GMED

Globus Medical (GMED) just cleared another earnings hurdle, posting quarterly profit and sales above consensus expectations while extending a four quarter streak of outperformance that keeps investor attention firmly on its fundamentals.

Globus Medical recently reported quarterly results that exceeded consensus forecasts for both adjusted earnings per share and revenue, continuing a pattern of outperformance over the past four quarters.

Globus Medical has delivered a strong multi year share price run, and the question now is whether that performance lines up with what its earnings can reasonably support.

Globus Medical (NYSE:GMED) introduced its SCRIPT patient-specific spinal implant platform at the 41st Annual North American Spine Society Meeting.

GMED vs. AXGN: Which Stock Is the Better Value Option?

Globus Medical recently used the 41st Annual North American Spine Society Meeting to showcase SCRIPT, an FDA cleared patient specific spinal implant platform, alongside its XLIF Prone Procedural Solution that combines a new patient positioner with the MaXcess…

Globus Medical (GMED) is back in the spotlight after using the 41st Annual North American Spine Society Meeting to unveil its SCRIPT patient specific spinal implant platform and XLIF Prone Procedural Solution.

Globus Medical (NYSE:GMED) introduced its SCRIPT patient specific spinal implant platform at NASS 2026 following FDA clearance.

Globus Medical has delivered a mixed share price story, with a strong multi year return sitting alongside shorter term pullbacks.